Fidaxomicin is ailing absorbed; therefore, austere adverse furnishings are rare. There are no accepted drug-drug interactions or contraindications with use. Fidaxomicin should not be used for systemic infections, and should be used alone for infections accurate or acerb doubtable to be acquired by C. difficile. Fidaxomicin is a U.S. Food and Drug Administration abundance class B drug; it is not accepted whether it is excreted in animal milk.

Fidaxomicin has an adverse aftereffect contour commensurable to that of articulate vancomycin. In analytic trials of 564 patients, about 6 percent withdrew because of adverse effects. The a lot of accepted adverse furnishings (greater than 5 percent) were nausea, vomiting, and belly pain.